GALECTIN THERAPEUTICS INC (GALT) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
GALT currently has 65.8M outstanding shares. with significant dilution risk as 84.8M authorized shares could dilute existing holders by 128.8%. The company has minimally diluted shareholders by 5.67% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Mar 31, 2026 |
S-3 filing: The filing is an S-3 form indicating the company may offer common stock, warrants, rights, and a combination thereof, with an aggregate initial offering price not exceeding $200,000,000. |
66M | 85M |
| Mar 31, 2026 |
10-K filing | 63.9M shares outstanding |
64M | 75M |
| Dec 19, 2025 |
8-K filing: Galectin Therapeutics Inc. entered into a Line of Credit Letter Agreement with Richard E. Uihlein, providing a line of credit of up to $10.00 million, and will issue warrants to purchase up to 200,000 shares of common stock to the lender. |
63M | 76M |
| Aug 14, 2025 |
10-Q filing | 63.4M shares outstanding |
63M | 76M |
| May 15, 2025 |
10-Q filing | 63.2M shares outstanding |
63M | 76M |
| Mar 31, 2025 |
10-K filing | 62.3M shares outstanding |
62M | 77M |
| Nov 14, 2024 |
10-Q filing | 62.3M shares outstanding |
62M | 77M |
| Aug 13, 2024 |
10-Q filing | 62.2M shares outstanding |
62M | 77M |
| May 15, 2024 |
10-Q filing | 62.0M shares outstanding |
62M | 77M |
| Mar 29, 2024 |
10-K filing | 60.2M shares outstanding |
60M | 79M |
| Nov 13, 2023 |
10-Q filing | 59.7M shares outstanding |
60M | 80M |
| Aug 14, 2023 |
10-Q filing | 59.6M shares outstanding |
60M | 80M |
| May 15, 2023 |
10-Q filing | 59.5M shares outstanding |
59M | 80M |
| Apr 14, 2023 |
S-3 filing: The company may offer and sell, from time to time, common stock, warrants, rights, and a combination thereof, at prices and on terms to be determined by market conditions and other factors at the time of our offerings. The aggregate initial offering price of all securities sold by us under this prospectus will not exceed $100,000,000. |
59M | 80M |
| Mar 30, 2023 |
10-K filing | 59.4M shares outstanding |
59M | 13M |
| Nov 14, 2022 |
10-Q filing | 59.4M shares outstanding |
59M | 13M |
| Aug 15, 2022 |
10-Q filing | 59.4M shares outstanding |
59M | 13M |
| Jul 26, 2022 |
8-K filing: Galectin Therapeutics Inc. entered into a Line of Credit Letter Agreement with Richard E. Uihlein for up to $60.00 million, with potential issuance of warrants to purchase up to 1,700,000 shares of common stock and conversion of promissory notes into common stock at a minimum price of $3.00 per share. |
59M | 13M |
| May 16, 2022 |
10-Q filing | 59.4M shares outstanding |
59M | 13M |
| Mar 31, 2022 |
10-K filing | 58.5M shares outstanding |
59M | 14M |
| Nov 15, 2021 |
10-Q filing | 59.3M shares outstanding |
59M | 13M |
| Aug 16, 2021 |
10-Q filing | 59.3M shares outstanding |
59M | 13M |
| May 17, 2021 |
10-Q filing | 58.1M shares outstanding |
58M | 14M |
| Mar 31, 2021 |
10-K filing | 57.2M shares outstanding |
57M | 15M |
| Nov 09, 2020 |
10-Q filing | 57.1M shares outstanding |
57M | 15M |
| Aug 10, 2020 |
10-Q filing | 57.0M shares outstanding |
57M | 15M |
| May 11, 2020 |
S-3 filing: The company may offer and sell common stock, warrants, rights, and a combination thereof, with an aggregate offering price not exceeding $100,000,000. The company intends to use the net proceeds of this offering for the continued development of our drug research and development programs, including the current NASH-RX trials for belapectin (GR-MD-02), and for general corporate purposes. |
57M | 15M |
| May 11, 2020 |
10-Q filing | 57.0M shares outstanding |
57M | 15M |
| Mar 16, 2020 |
10-K filing | 56.9M shares outstanding |
57M | 0 |